---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-043363"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:22:52.912049+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology Q2 net loss widens to $7.7M; cash only $112, needs funding beyond May 2025

## Summary
- Net loss of $7.7M ($0.11 per share) vs $4.8M loss a year ago; R&D and G&A expenses increased due to launch activities.
- Cash and equivalents at March 31, 2025 totaled just $112; company requires additional capital to sustain operations beyond May 2025.
- Retained Jefferies LLC as exclusive financial advisor to evaluate strategic alternatives aimed at maximizing stockholder value.
- Advancing commercial launch of LYMPHIR (cutaneous T-cell lymphoma) after FDA approval; discussions with partners ongoing.

## SEC filing metadata
- accession: 0001213900-25-043363
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025043363/0001213900-25-043363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025043363/ea0241972-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-043363
- JSON: https://secwatch.observer/filing/0001213900-25-043363.json
- Plain text: https://secwatch.observer/filing/0001213900-25-043363.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.